<p>To correct for survival bias, this analysis was limited to ISKS participants prospectively recruited from 2007 onwards (<i>TP53</i> mutation carriers, n = 11; Non-carriers, n = 420).</p
<p>Curves showing the overall survival starting with the time point of tumor biopsy in 82 metastatic...
<p>A. Overall survival by cytogenetics and mutational profiles. Among patients with intermediate cyt...
<p>Curves showing the overall survival of 109 metastatic melanoma patients starting from the time po...
<p>(A) Carriers of the <i>TP53</i> rs12951053 C or rs12602273 G alleles had significantly worse 4-ye...
<p>Kaplan-Meier curves of disease-free (left) and overall (right) survival in patients categorized o...
<p>Log Rank (Mantel-Cox) test showing that patients who harbor (a) overall <i>TP53</i> and oncogenic...
<p>WT, wild-type; <i>TP53</i>+<i>CHEK2</i> mut, all found mutations in <i>TP53</i> and <i>CHEK2</i>;...
Survival and disease-free survival time of patients with or without specific gene mutations were ana...
<p>(A) The survival rate was worse in <i>RFC1 80AA</i> (22.2%) patients as compared to the <i>RFC1 8...
<p>Kaplan-Meier survival curves of patients with wild type (n = 50) vs. mutant (n = 27) <i>K-ras</i>...
<p>Kaplan-Meier survival analysis of CDCS cohort stratified by rs6922269 genotype a) in patients wit...
<p>Kaplan-Meier survival analysis of CDCS cohort patients stratified by rs6922269 genotype.</p
<p>Kaplan Meier estimates comparing intent-to-treat Group 1 to unvaccinated control Group 3 for (A) ...
<p>Patients overall survival analyses were made between two groups: (A) patients with or without mut...
<p>Kaplan-Meier cumulative survival curves for SAE (HF death, OHT or LVAD) in 46 carriers of <i>TTN<...
<p>Curves showing the overall survival starting with the time point of tumor biopsy in 82 metastatic...
<p>A. Overall survival by cytogenetics and mutational profiles. Among patients with intermediate cyt...
<p>Curves showing the overall survival of 109 metastatic melanoma patients starting from the time po...
<p>(A) Carriers of the <i>TP53</i> rs12951053 C or rs12602273 G alleles had significantly worse 4-ye...
<p>Kaplan-Meier curves of disease-free (left) and overall (right) survival in patients categorized o...
<p>Log Rank (Mantel-Cox) test showing that patients who harbor (a) overall <i>TP53</i> and oncogenic...
<p>WT, wild-type; <i>TP53</i>+<i>CHEK2</i> mut, all found mutations in <i>TP53</i> and <i>CHEK2</i>;...
Survival and disease-free survival time of patients with or without specific gene mutations were ana...
<p>(A) The survival rate was worse in <i>RFC1 80AA</i> (22.2%) patients as compared to the <i>RFC1 8...
<p>Kaplan-Meier survival curves of patients with wild type (n = 50) vs. mutant (n = 27) <i>K-ras</i>...
<p>Kaplan-Meier survival analysis of CDCS cohort stratified by rs6922269 genotype a) in patients wit...
<p>Kaplan-Meier survival analysis of CDCS cohort patients stratified by rs6922269 genotype.</p
<p>Kaplan Meier estimates comparing intent-to-treat Group 1 to unvaccinated control Group 3 for (A) ...
<p>Patients overall survival analyses were made between two groups: (A) patients with or without mut...
<p>Kaplan-Meier cumulative survival curves for SAE (HF death, OHT or LVAD) in 46 carriers of <i>TTN<...
<p>Curves showing the overall survival starting with the time point of tumor biopsy in 82 metastatic...
<p>A. Overall survival by cytogenetics and mutational profiles. Among patients with intermediate cyt...
<p>Curves showing the overall survival of 109 metastatic melanoma patients starting from the time po...